Sangrail Biologics Launches with Gene Therapy Hope for Children with Fatal Genetic Disease

CLEVELAND, OH – May 05, 2026 – A new clinical-stage company, Sangrail Biologics, launched today from Cleveland, carrying the weight of a mission its CEO describes as “restoring life’s blueprint.” The company emerges with a singular focus on children with rare genetic diseases and a powerful lead asset: SNG-101, a late-stage gene therapy for the devastating neurodegenerative condition mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B.

For families navigating the brutal progression of MPS IIIB, the launch represents a significant milestone. The disease, which has no approved treatments, relentlessly steals a child’s ability to speak, think, and move, with most not living to see their 18th birthday. Sangrail’s SNG-101, a one-time intravenous gene therapy, aims to halt this decline by directly addressing the genetic root cause of the disorder.

“Our mission of restoring life’s blueprint is a promise we are making to the families whose children are fighting battles against conditions that currently have no cure,” said Timothy J. Miller, Ph.D., CEO, Chairman, and Co-Founder of Sangrail Biologics. “We are here to transform these diagnoses from a path of decline into a future defined by biological restoration, potential, and hope.”

The Devastating Landscape of MPS IIIB

MPS IIIB is a rare autosomal recessive lysosomal storage disease with an estimated incidence of around 1 in 200,000 newborns. It is caused by mutations in the NAGLU gene, which prevents the body from producing a critical enzyme needed to break down a complex sugar molecule called heparan sulfate. Without this enzyme, heparan sulfate accumulates to toxic levels within cells, particularly in the brain.

The result is a catastrophic and progressive decline. Children with MPS IIIB often appear healthy at birth but begin to show developmental delays in early childhood. This is followed by severe hyperactivity, behavioral problems, intellectual decline, loss of speech, and loss of mobility. The profound neurological damage is irreversible, and current medical care is limited to managing symptoms and providing supportive care to improve quality of life, offering no hope of a cure.

This dire unmet need has driven researchers for decades to find a way to deliver a functional gene to the central nervous system, a feat complicated by the protective blood-brain barrier. The launch of Sangrail and the advancement of SNG-101 signal a potential turning point in this long battle.

A Legacy of Science and Promising Clinical Data

SNG-101 is not an overnight discovery. The therapy, formerly known as ABO-101, has a long development history originating from foundational work at Nationwide Children's Hospital and advanced into the clinic by Abeona Therapeutics. Sangrail Biologics is now carrying this torch forward. The therapy uses a specifically chosen vector, an adeno-associated virus serotype 9 (AAV9), which is renowned for its ability to cross the blood-brain barrier and deliver its genetic payload to the brain and spinal cord after a single intravenous injection.

The goal is simple in concept but complex in execution: deliver a correct copy of the NAGLU gene to the body’s cells, enabling them to produce the missing enzyme and halt the toxic buildup of heparan sulfate. Early clinical data from the program, which has already treated 14 children across a global Phase 1/2 trial and named-patient programs, suggests the therapy is doing just that.

According to the company, patients treated with SNG-101 showed rapid and sustained biological improvements. Key biomarkers of disease activity dropped significantly. Heparan sulfate, the toxic substance at the heart of the disease, was significantly reduced in the cerebrospinal fluid (CSF), urine, and plasma. The missing NAGLU enzyme activity was restored to normal levels in the plasma and CSF. Critically, biomarkers of neuronal loss also decreased, suggesting the therapy may protect the brain from further damage.

“MPS IIIB is a devastating and progressive lysosomal storage disease with few treatment options,” stated Kevin M. Flanigan, MD, principal investigator and Director of the Center for Gene Therapy at Nationwide Children's Hospital. He noted that beyond the biomarker data, “Importantly, we also see improvements or stabilization of neurocognitive function in the youngest treated patients.” This observation is the most crucial sign of hope for families, as it suggests that if administered early enough, SNG-101 could preserve a child's developmental potential.

A Strategic Pathway to Approval

Bringing a multi-million dollar gene therapy for an ultra-rare disease to market is a monumental challenge, but Sangrail Biologics appears to be on a firm footing. The SNG-101 program has already secured a robust package of regulatory designations that create an expedited path toward potential approval.

In the United States, the FDA has granted the program Fast Track, Orphan Drug, and Rare Pediatric Disease Designations. Fast Track facilitates more frequent communication with the FDA and allows for a rolling review of the marketing application, while Orphan Drug designation provides seven years of market exclusivity upon approval. The most financially significant of these is the Rare Pediatric Disease Designation, which makes Sangrail eligible to receive a Priority Review Voucher (PRV) if SNG-101 is approved. These vouchers, which can be used to accelerate the review of a future drug or be sold to another company for tens of millions of dollars, provide a critical source of non-dilutive capital for emerging biotech firms.

The program has also received Orphan Drug Designation from the European Medicines Agency (EMA), smoothing its path in Europe. These regulatory milestones not only validate the clinical importance of the therapy but also provide a strategic commercial advantage that is vital for a small company tackling an ultra-rare disease.

This progress has been lauded by patient advocates. “The strength of the SNG-101 clinical data generated over these years of follow-up tells a compelling story of potential and rigorous scientific achievement,” stated Terri Klein, CEO of the USA National MPS Society. “We fully support the efforts to accelerate access to this gene therapy, as it represents exactly the kind of breakthrough progress our community has been fighting for.”

Michelle Berg, President, COO, and Co-Founder of Sangrail, emphasized the collaborative nature of the program. “We are profoundly grateful to the families whose commitment to this program and long-term follow-up has been the backbone of our progress,” she said. Now, all eyes in the MPS community are turning to Boston, where the full, detailed results from the Phase 1/2 clinical trial will be presented at the annual meeting of the American Society of Gene and Cell Therapy on May 13, a presentation that could mark a new chapter for every child diagnosed with Sanfilippo syndrome.